BiomX Inc. (PHGE) Bundle
Understanding BiomX Inc. (PHGE) Revenue Streams
Revenue Analysis
The company's revenue analysis reveals critical financial insights for investors.
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $14.6 million | -32.5% |
| 2023 | $11.3 million | -22.6% |
Revenue streams breakdown includes:
- Research Services: 68% of total revenue
- Product Development: 22% of total revenue
- Licensing Agreements: 10% of total revenue
| Geographic Revenue Distribution | Percentage |
|---|---|
| North America | 62% |
| Europe | 28% |
| Asia-Pacific | 10% |
Key revenue performance indicators highlight significant market challenges and strategic repositioning.
A Deep Dive into BiomX Inc. (PHGE) Profitability
Profitability Metrics Analysis
Financial performance metrics reveal critical insights into the company's profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -72.5% |
| Operating Profit Margin | -237.4% | -212.6% |
| Net Profit Margin | -241.5% | -226.8% |
Key profitability observations include:
- Gross profit margin improved marginally from -72.5% to -68.3%
- Operating expenses remain significantly high relative to revenue
- Net losses continue to represent substantial financial challenge
Research and development expenditures for 2023 totaled $48.3 million, representing 89.7% of total operating expenses.
| Expense Category | 2023 Amount |
|---|---|
| R&D Expenses | $48.3 million |
| Sales & Marketing | $3.2 million |
| General & Administrative | $5.1 million |
Cash burn rate for 2023 was $57.6 million, indicating continued investment in core technological development.
Debt vs. Equity: How BiomX Inc. (PHGE) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $42.6 million | 67% |
| Total Short-Term Debt | $20.8 million | 33% |
| Total Debt | $63.4 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.22
- Weighted Average Cost of Debt: 6.3%
Equity Financing Details
| Equity Component | Amount | Percentage |
|---|---|---|
| Common Stock | $87.5 million | 58% |
| Preferred Stock | $22.3 million | 15% |
| Additional Paid-in Capital | $40.2 million | 27% |
Recent Financing Activity
- Credit Rating: B+ (Standard & Poor's)
- Latest Bond Issuance: $25 million at 5.75% interest
- Equity Raise in 2023: $45.6 million
Assessing BiomX Inc. (PHGE) Liquidity
Liquidity and Solvency Analysis
BiomX Inc. financial liquidity metrics reveal critical insights for potential investors:
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.24 | 1.18 |
| Quick Ratio | 1.09 | 1.05 |
| Working Capital | $14.6 million | $12.3 million |
Cash flow statement highlights:
- Operating Cash Flow: $-8.2 million
- Investing Cash Flow: $-5.7 million
- Financing Cash Flow: $22.1 million
Liquidity position indicators:
| Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $37.4 million |
| Short-term Investments | $15.6 million |
| Total Liquid Assets | $53 million |
Key solvency metrics demonstrate moderate financial stability with potential areas of improvement in operational cash generation.
Is BiomX Inc. (PHGE) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for this biotechnology company reveals critical insights into its current market positioning and investor perception.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -8.45 |
| Price-to-Book (P/B) Ratio | 1.23 |
| Enterprise Value/EBITDA | -12.67 |
| Current Stock Price | $3.45 |
Stock price trends demonstrate significant volatility over the past 12 months:
- 52-week low: $2.18
- 52-week high: $5.67
- Price decline: 39.2%
Analyst consensus provides additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 35% |
| Hold | 45% |
| Sell | 20% |
Dividend metrics indicate the following:
- Dividend Yield: 0%
- Payout Ratio: N/A
Key Risks Facing BiomX Inc. (PHGE)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and market position:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $14.2 million cash balance as of Q3 2023 |
| Revenue Volatility | Uncertain Revenue Streams | -$22.1 million net loss in fiscal year 2023 |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Technology Development Risks
Market Risks
Key market-related risks include:
- Competitive Biotechnology Landscape
- Potential Funding Constraints
- Intellectual Property Protection Challenges
Regulatory Risks
Potential regulatory challenges include:
| Regulatory Area | Risk Level | Potential Consequence |
|---|---|---|
| FDA Approval Process | High | Potential Delay in Product Commercialization |
| Compliance Requirements | Medium | Potential Financial Penalties |
Investment Risks
Investors should consider the following financial metrics:
- Stock Price Volatility: ±15% quarterly fluctuation
- Research and Development Expenses: $18.3 million in 2023
- Burn Rate: Approximately $5.6 million per quarter
Future Growth Prospects for BiomX Inc. (PHGE)
Growth Opportunities
BiomX Inc. demonstrates potential growth opportunities through several strategic avenues:
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size by 2027 |
|---|---|---|
| Microbiome Therapeutics | 23.4% | $5.7 billion |
| Precision Medicine | 15.2% | $3.9 billion |
Strategic Research Initiatives
- Phage therapy development pipeline with 4 active clinical programs
- Investment of $12.3 million in R&D for 2024
- Targeting rare disease indications with unmet medical needs
Competitive Technology Advantages
Key technological differentiators include:
- Proprietary microbiome engineering platform
- Advanced phage selection algorithms
- Personalized therapeutic approach
Revenue Growth Projections
| Year | Projected Revenue | Year-over-Year Growth |
|---|---|---|
| 2024 | $18.5 million | 35.6% |
| 2025 | $25.3 million | 36.8% |
BiomX Inc. (PHGE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.